Crescent Biopharma, Inc. (CBIO)
| Market Cap | 499.96M+19.5% |
| Revenue (ttm) | 11.88M |
| Net Income | -162.98M-152.2% |
| EPS | -7.58+88.9% |
| Shares Out | 37.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jan 13, 2023 |
| Volume | 25,952.597 |
| Open | 13.39 |
| Previous Close | 13.49 |
| Day's Range | 12.98 - 13.53 |
| 52-Week Range | 8.72 - 27.41 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 36.00(+167.46%) |
| Earnings Date | Nov 5, 2026 |
CRESCENT BIOPHARMA, INC. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CBIO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CBIO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CBIO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CBIO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CBIO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Personnel costs | $11.24M | 62.02% |
| Professional and other fees | $4.38M | 24.18% |
| Milestone and license fees | $2.50M | 13.79% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CBIO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CBIO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CBIO
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $15.05M |
| IWMiShares Russell 2000 ETF | $10.10M |
| XBIState Street SPDR S&P Biotech ETF | $4.73M |
| IWOiShares Russell 2000 Growth ETF | $3.68M |
| VTWOVanguard Russell 2000 ETF | $2.06M |
| VXFVanguard Extended Market ETF | $1.39M |
Estimated from each fund’s disclosed top holdings × AUM
CBIO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CBIO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score